Article
-
Article
Congress must fix the IRA’s small molecule penalty
03.06.2023
"But the IRA is changing the calculus in a meaningful — and harmful — way."
-
Video
The Inflation Reduction Act- Explained by Incubate
12.15.2022
Incubate breaks down the Inflation Reduction Act, diving into implications and potential impacts on life science development. Keep up with...
-
Article
US Government Poised for Long-Awaited Powers on Drug Pricing
08.06.2022
Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated
-
Article
HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
08.04.2022
Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.
-
Article
Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
08.03.2022
Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.
-
Article
Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
08.03.2022
A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.
-
Article
LTE: Patents protect people’s access to life-saving medicine
06.05.2022
See Incubate's letter to the editor about why patents are necessary in protecting patient access.
-
Article
To Spend Less on Healthcare, Invest in More Medicines
04.05.2022
Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.
-
Article
CMS’s Devastating Blow to Seniors
02.09.2022
Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.
-
Article
Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
12.02.2021
A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.
-
Article
House passage of Build Back Better gets mixed reaction
11.22.2021
As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.
-
Article
Regeneron, Janssen Drugs Fit Profile Targeted in Spending Bill
11.10.2021
Plan would negotiate prices of expensive older pharmaceuticals Moderate Democrats sought compromise to preserve innovation